Overview
Health care cost to society has risen to levels which are no longer sustainable.
This fund invests globally in innovative companies which are driving a revolution in the health care sector through the application of technology.
The investment universe comprises three segments: Research & Development, Treatments and Efficiency. The fund invests in “pure-play” digital health companies, which are typically small to mid-sized.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
Benefits
Offers diversified exposure to the digital health universe, which is one of the fastest growing segments in the health care industry.
The investment objective is long-term capital appreciation from actively managed exposure to this secular growth theme.
Risks
Features
| Product category |
UBS Thematic Funds
|
| Product domicile |
Luxembourg
|
| Portfolio management |
UBS SA国际传谋 (Americas) LLC, New York
|
| Fund management |
UBS SA国际传谋 (Europe) S.A., Luxembourg
|
| Custodian bank |
UBS Europe SE, Luxembourg Branch
|
| Representative for products established under foreign law |
UBS Europe SE, sucursal en España
|
| Day of inception |
February 14, 2018
|
| Currency of account |
EUR
|
| Close of financial year |
May 31
|
| SFDR Classification |
Art.8
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
0.99% p.a.
|
| Management fee |
0.76% p.a.
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
MSCI AC World (NR) (EUR hedged)
|
| ISIN |
LU1683287889
|
| Bloomberg Ticker |
CSGDEBH LX
|
| Reuters Id |
38312180X.CHE
|
Performance and Prices
Percentage growth
as of April 23, 2026| EUR(%) | |
| YTD | |
| 1M | |
| 3M | |
| 6M | |
| 1Y | |
| 2Y | 9.22 |
| 3Y | |
| 5Y | -51.96 |
| ø p.a.5Y | -13.64 |
Current data
| Net asset value | 23.04.2026 | EUR 1,094.64 |
| High - last 12 months | 07.01.2026 | EUR 1,240.75 |
| Low - last 12 months | 30.03.2026 | EUR 1,008.96 |
| Assets of the unit class in mn | 23.04.2026 | EUR 6.35 |
| Total product assets in mn | 23.04.2026 | EUR 465.42 |
Structures
By the 10 largest positions (in %, as of March 31, 2026)
|
|
|
| Intuitive Surgical Inc | 3.57 |
| Guardant Health Inc | 3.53 |
| Arrowhead Pharmaceuticals Inc | 3.20 |
| Alcon AG | 3.13 |
| Kymera Therapeutics Inc | 3.12 |
| Denali Therapeutics Inc | 3.11 |
| IRhythm Holdings Inc | 3.05 |
| Koninklijke Philips NV | 2.99 |
| CG oncology Inc | 2.97 |
| Ionis Pharmaceuticals Inc | 2.78 |
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
| Fact Sheet |
|
| Fact Sheet - UBS Thematic Funds |
|
Document type
|
Document Language
|
|
| Prospectus |
|
|
| Key Information Document |
|
|
| Past performance |
|
|
| Previous performance scenario |
|
|
| Statutes / Management regulations |
|
|
Document type
|
Document Language
|
| Annual report |
|
| Semi-annual report |
|